Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ESLA
Strong SellSinkerEstrella Immunopharma, Inc. · Healthcare · United States · $62M · Avg Vol: $19K/d
COMPANY DESCRIPTION
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies to treat blood cancers and solid tumors. The company's proprietary ARTEMIS platform is designed to target cancer cells while minimizing life-threatening side effects like cytokine release syndrome. This innovative technology positions Estrella as a niche player in the highly competitive oncology immunotherapy market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.05 | -0.32 | -0.27 | -0.35 | — | -0.25 | -0.29 | -0.32 | — |
| Shares | 35.2M | 35.2M | 36.3M | 38.0M | +7.9% | 43.5M | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — |
| Equity | -1.0M | -11.7M | 4.3M | -10.4M | — | — | — | — | — |
| Op CF | -1.4M | -1.3M | -16.1M | -1.8M | — | -9.4M | — | — | — |
| Inv CF | 0 | -0.3M | 5.0M | — | — | — | — | — | — |
| Fin CF | 5.5M | 0 | 12.8M | 2.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ESLA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ESLA | Estrella Immunopharma, Inc.(you) | $62M | 1 | Strong Sell |
| EXOZ | eXoZymes, Inc. | $67M | 2 | Strong Sell |
| RNTX | Rein Therapeutics Inc. | $66M | 2 | Strong Sell |
| IBIO | iBio, Inc. | $68M | 3 | Strong Sell |
| 2257.HK | Sirnaomics Ltd. | $55M | 1 | Strong Sell |
| FLNA | Filana Therapeutics, Inc. | $58M | 4 | Strong Sell |
| ELTX | Elicio Therapeutics, Inc. | $75M | 2 | Strong Sell |
| HRTX | Heron Therapeutics, Inc. | $62M | 7 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| GOSS | Gossamer Bio, Inc. | $83M | 2 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%